Trifluoperazine is a dopamine D2 receptor inhibitor with IC50 of 1.1 nM.

Trifluoperazine binds to α1A- and α1B-adrenoceptor with Ki value of 27.6 nM and 19.2 nM, respectively, with α1B/α1A ratio of 0.7. [2] Trifluoperazine inhibits Mycobacterium tuberculosis (Mtb) with MICs of 7.6 μg/mL. [3]Trifluoperazine (< 14.78 mM) suppresses the activities of the mouse splenic NK cell cytotoxicity and the effector-target cell conjugation in a dose dependent manner. Trifluoperazine suppresses interferon-alpha or interleukin-2 induced augmentation of the cytolytic activity of NK cells. [4] Trifluoperazine inhibits the gene expression of voltage-dependent potassium channel Kv2.1 from human brain (hKv2.1). [5]

 Trifluoperazine dose dependently decreases avoidance responses and increases response failures in rats where behavior is maintained under a discrete-trial avoidance. [6]

References

[1] Lahti RA, et al. Eur J Pharmacol, 1993, 236(3), 483-486.

[2] Cahir M, et al. Eur Neuropsychopharmacol, 2005, 15(2), 231-234.

转载本文请联系原作者获取授权，同时请注明本文来自陈达科学网博客。
链接地址：https://blog.sciencenet.cn/blog-2321593-932778.html

上一篇：Temozolomide is a DNA damage inducer in L-1210 and L-1210/BC
下一篇：MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3